Not all variants have the same levels of evidence behind them, (see our post on KIT mutations to understand this better). While most knowledge bases online tend to report solely on those which are clinically actionable, StrandIRIS provides information on both those variants and variants which are AMP Tier 2 or 3 (with less clinical evidence behind them).
Take for instance a patient who has the A598V variant in the BRAF gene. While not a clinically actionable variant yet, it is deemed likely oncogenic and has been implicated in certain cancers. While a brief note of the variant may be found in other knowledge-bases, StrandIRIS is able to provide context. The functional implication of the variant is included, with links to the evidence behind it, as well as a quick summary. Along with this, information on actionable drugs for other variants of the BRAF gene (such as V600) are included for other treatment options.
As we saw in the last post, both FDA approved drugs and other investigational drugs as well as ongoing clinical trials are included.
